Intangible Assets

AQST’s approved products and regulatory filings create some protection, but the portfolio is narrower than larger specialty pharma peers with broader marketed franchises and deeper label breadth.

The company’s value is tied to FDA-approved formulations and REMS/label execution, which can support differentiation, but peers with more diversified pipelines and commercial scale can still compete on physician access and payer leverage.

Compared with larger branded-drug peers, AQST’s intangible asset base is less durable because it lacks a broad patent moat or category-defining brand that consistently sustains pricing power across multiple products.

Switching Costs

Prescriber and payer switching costs are limited because branded therapeutics in AQST’s categories are typically chosen based on clinical profile, coverage, and contracting rather than deep workflow lock-in.

AQST can benefit from formulary placement and patient familiarity once adopted, but peers with larger portfolios and stronger payer relationships can displace share more easily than in software-like or device-integrated markets.

The company does not appear to have the kind of embedded clinical workflow dependence that would make customers materially reliant on AQST versus alternative branded or generic options.

Network Effects

AQST does not operate a platform business where each additional user materially increases value for other users, so there is no meaningful direct network effect.

Unlike peers in data-rich or ecosystem-driven healthcare models, AQST’s products do not become more defensible as adoption rises beyond normal commercial scale benefits.

Any physician or patient familiarity is local and product-specific rather than self-reinforcing across a broader network, so it does not create durable peer-leading moat strength.

Cost Advantage

AQST’s TTM ROIC and ROCE are deeply negative, which indicates the company is not currently converting its commercial base into a cost advantage versus peers.

Its cash conversion cycle is positive and manageable, but that reflects working-capital mechanics rather than a structural manufacturing or sourcing edge over larger competitors.

Compared with larger specialty pharma peers that can spread SG&A, regulatory, and manufacturing overhead across more products, AQST appears disadvantaged on unit economics rather than advantaged.

Efficient Scale

AQST operates in niche therapeutic areas where market size can limit the number of viable competitors, which can modestly support efficient scale relative to broad primary-care peers.

However, the company’s scale is not so dominant that rivals are excluded, because larger specialty pharma firms can still enter with stronger commercialization resources and broader portfolios.

The niche nature of the markets helps somewhat, but it does not rise to the level of peer-dependent industry control or a durable scale moat.

Overall Score

AQST shows some moat support from regulatory protection and niche-market positioning, but the overall durability is limited by weak switching costs, no network effects, and no demonstrated cost advantage versus larger specialty pharma peers.